Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Indivior Pharmaceuticals, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-69.5% vs price
Base Case (Median)
-47.8% vs price
Bull Case (75th pct.)
-7.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $13.86 | -61.2% | High (40%) |
| PE Comparable | $62.65 | 75.4% | Medium (25%) |
| EV/EBITDA | $23.39 | -34.5% | Medium (20%) |
| Earnings Power Value | $1.96 | -94.5% | Medium (50%) |
Based on 4 out of 7 methods, INDV appears overvalued at the current price of $35.71. The base case fair value of $18.63 implies 47.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.